Drugs / CENPLACEL-L
CENPLACEL-L
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01859117 | May 2013 → Oct 2016 | peripheral arterial disease, ulcer of lower limbs | Celularity Incorporated | Completed | No outcome recorded |
| Phase 23 trials · 1 met primary | ||||||
| Phase 2 | NCT02552277 | Oct 2015 → Mar 2017 | diabetic kidney disease, peripheral neuropathy | Celularity Incorporated | Completed | No outcome recorded |
| Phase 2 | NCT02460081 | Jun 2015 → Jan 2016 | peripheral arterial disease | Celularity Incorporated | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02264288 | Oct 2014 → Feb 2018 | peripheral arterial disease | Celularity Incorporated | Terminated | Met primary Stop: Business |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-10-14 | Celularity Incorporated | Results Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease celularity.com ↗
Results of this study demonstrated safety and efficacy in a complex type of serious wounds in the setting of diabetes and peripheral vascular disease. |
| 2024-03-20 | Celularity Incorporated | Regulatory Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy celularity.com ↗ |
All press releases naming this drug 3 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CENPLACEL-L | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107867 ↗ |
| Known as | cenplacel | “The objective of this study was to examine the safety of cenplacel (PDA-002) in patients with peripheral arterial disease (PAD) and a diabetic foot ulcer (DFU).” PMID 28133924 ↗ Jan 2017 |
| Known as | PDA-001 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107867 ↗ |
| Known as | PDA-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01859117 ↗ |
| Modality | Cell therapy | “PDA-002, a human placenta-derived cell therapy” NCT01859117 ↗ |
| Route | Intramuscular | “administered intramuscular (IM)” NCT02460081 ↗ |